Pioneer and Innovator

Quest Diagnostics has been recognized for four decades as a Pioneer and Innovator, bringing new tests and technologies to physicians and their patients. This success is built upon our investments in scientists and their research, our building bridges with academia and biotech firms through the Nichols Institute Academic Associates and licensing agreements, and our collaborations with healthcare organizations and providers. Thousands of tests have been introduced and improved, many first commercialized through Quest Diagnostics. Our Vision reinforces our commitment to innovation so that we improve the health of patients through unsurpassed diagnostic insights and innovation.

Selected Highlights in the History of Quest Diagnostics

2008
Quest Diagnostics establishes clinical laboratory operations in India to serve the growing demand for high quality, specialized testing in India.
Focus Diagnostics, Inc, a Quest Diagnostics company, announces the first PCR-based test developed in the USA for detecting mosquito-borne chikungunya virus.
Quest Diagnostics announces licensing rights to a DNA methylation marker from Epigenomics that will be used to develop a test to detect colorectal cancer.
Quest Diagnostics is recognized by Fortune magazine as one of America's "most admired companies".
2007
Quest Diagnostics acquires AmeriPath, the leader in anatomic pathology to further its support of cancer diagnostics.
Quest Diagnostics introduces ClariSure™ for identifying chromosomal abnormalities associated with 85 developmental disorders in children. ClariSure is a microarray-based comparative genomic hybridization test.
2006-2007 
Quest Diagnostics completes the acquisitions of Focus Diagnostics, a world leader in tests for infectious diseases, Enterix, Inc. (Australia) developer of InSure™ Fecal Immunochemical Test, and HemoCue™ (Sweden) that specializes in near-patient testing. These acquisitions position Quest Diagnostics as a worldwide manufacturer of specialized testing especially point-of-care/near-patient testing.
Quest Diagnostics is the first reference laboratory to provide calculated eGFR results to improve detection and management of patients with chronic kidney disease.
2005
Quest Diagnostics acquires LabOne and enters into the risk assessment business to support the life insurance industry. LabOne has a Canadian subsidiary based in Ontario, Canada.
2003
Quest Diagnostics introduces mass spectrometric steroid testing for differential diagnosis of congenital adrenal hyperplasia (CAH) in infants and 21-hydroxylase deficiency CAH gene mutations for at-risk screening and disease management.
2001
Quest Diagnostics becomes the first laboratory to utilize transcription mediated amplification technology in hepatitis C virus testing. Heptimax™ is approximately ten-fold more sensitive than any other commercial test.
1999
Quest Diagnostics acquires its slightly larger competitor SmithKline Beecham Clinical Laboratories (SBCL) to further consolidate the independent laboratory industry and become the undisputed leader in diagnostic testing, information, and services. Included in the acquisition was the European operations of SBCL based in Heston, outside London, UK.
Quest Diagnostics is the first reference laboratory to offer Cardio CRP™ as an independent biomarker of cardiovascular disease risk.
1998
Chairman and CEO Kenneth W. Freeman lays out the challenge for Quest Diagnostics to be a Six Sigma Quality company.
Nichols Institute becomes the first clinical laboratory in North America to become ISO 9001 certified.
1997
Quest Diagnostics becomes a public company, spun-off from Corning, trading on the New York Stock Exchange (ticker symbol DGX).
Quest establishes Quest do Brasil Ltda, based in Sao Paulo, Brazil.
1994
Corning acquires Nichols Institute, world-renowned for its role in introducing new esoteric tests.
Corning Clinical Laboratories is the first laboratory to offer a full testing menu in molecular HIV/AIDS testing.
1993
As part of Corning Clinical Laboratories acquisition of regional laboratory Damon, Laboratories de Frontera in Mexico City that starts the international expansion.
1984-1992 
Nichols Institute continues introducing new endocrinology tests that provide new insights into thyroid disease, diabetes, and adrenal disorders. New tests include: thyroid binding inhibitory immunoglobulin, thyroid stimulating immunoglobulin, TSH antibody, T4 antibody, T3 antibody, Thyroid peroxidase antibody, and thyrotropin releasing hormone — to name a few.
1982-2002 
Corning Incorporated purchases MetPath. In the following two decades, consolidation continues with the acquisitions of Damon, Maryland Medical Laboratories, Bioran, American Medical Laboratories, UniLab, and hundreds of other clinical laboratories.
1975+
MetPath becomes a pioneer in offering hemoglobin A1c to monitor control in patients with diabetes, in 1977, HDL cholesterol to detect "good" cholesterol, and expanded chemistry panels (ChemScreen™) that provides new diagnostic insights in early detection of many health conditions. Nichols Institute pioneers estrogen receptor (ER) testing and two years later, progesterone receptor (PR) testing that guides therapy in patients with breast cancer.
1971+
Dr. Albert Nichols, endocrinologist, and fellow colleagues found Nichols Institute, based in San Juan Capistrano, California, with the mission of identifying new endocrinology tests that detect concentrations of hormones. Nichols Institute is a pioneer in offering tests for thyroid function, TSH in newborns to detect cretinism, follicle stimulating hormone (FSH), lutenizing hormone (LH), in 1973, plasma renin activity (PRA), and in 1974, parathyroid hormone (PTH) — to name just a few.
1969
SmithKline Beecham enters the clinical laboratory testing market with its acquisition of four independent laboratories in Boston, San Francisco, Dallas, and Tampa.
1967
Dr. Paul Brown, pathologist, found Metropolitan Pathology Services Incorporated (MetPath Inc.) in New York City with a new concept for highly-automated, high-quality, and low-cost clinical laboratory testing. MetPath quickly grows to become the leading clinical laboratory in the New York City area.

Bookmark/Search this site
Delicious    Google    Yahoo    Technorati